Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors
This image was generated by AI and may not depict real events.
Achieve Life Sciences has appointed Andrew D. Goldberg, MD, as its new CEO and added two new members to its Board of Directors. The company is preparing to launch cytisinicline, a potential new treatment for nicotine dependence.
Achieve Life Sciences has appointed Andrew D. Goldberg, MD, as its new CEO, effective after a recent financing deal. Dr. Goldberg is a dual board-certified physician with experience in healthcare investment and commercial strategy. The company has also added Lucian Iancovici, MD, and Aaron E. Royston, MD, to its Board of Directors. Achieve is advancing cytisinicline, a potential new treatment for nicotine dependence, toward FDA approval. The company's outgoing CEO, Richard Stewart, will remain on the Board. Achieve has secured up to $354 million in financing to support the development and launch of cytisinicline.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.